our Premium Content: News alerts, weekly reports and conference planners
DRUG:
CD19 CAR T cells
i
Other names: CD19 CAR T cells, CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem-enriched T-lymphocytes, CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem-enriched T Cells, CD19R(EQ)28zeta/EGFRt+ Naive and Memory T Cells, CD19R(EQ)28zetaEGFRt+ Tn/mem Cells
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
P2, N=36, Recruiting, City of Hope Medical Center | Trial completion date: Sep 2024 --> Dec 2024 | Trial primary completion date: Sep 2024 --> Dec 2024
1 month ago
Trial completion date • Trial primary completion date • CAR T-Cell Therapy • Immune cell
P1, N=24, Recruiting, City of Hope Medical Center | Trial completion date: Aug 2025 --> Dec 2026 | Trial primary completion date: Aug 2025 --> Dec 2026
3 months ago
Trial completion date • Trial primary completion date • CAR T-Cell Therapy
|
Erbitux (cetuximab) • cyclophosphamide • fludarabine IV • CD19 CAR T cells
P1, N=37, Active, not recruiting, City of Hope Medical Center | Trial completion date: Dec 2023 --> Dec 2024 | Trial primary completion date: Dec 2023 --> Dec 2024
9 months ago
Trial completion date • Trial primary completion date
|
CD19 positive
|
cyclophosphamide • etoposide IV • fludarabine IV • Belrapzo (bendamustine RTD) • CD19 CAR T cells
P1, N=51, Active, not recruiting, City of Hope Medical Center | Trial completion date: Dec 2023 --> Dec 2024 | Trial primary completion date: Dec 2023 --> Dec 2024
9 months ago
Trial completion date • Trial primary completion date
P2, N=36, Recruiting, City of Hope Medical Center | Trial completion date: Dec 2023 --> Sep 2024 | Trial primary completion date: Dec 2023 --> Sep 2024
over 1 year ago
Trial completion date • Trial primary completion date • CAR T-Cell Therapy • Immune cell
P1, N=51, Active, not recruiting, City of Hope Medical Center | Trial completion date: Dec 2022 --> Dec 2023 | Trial primary completion date: Dec 2022 --> Dec 2023
over 1 year ago
Trial completion date • Trial primary completion date
P1, N=71, Active, not recruiting, City of Hope Medical Center | Trial completion date: Dec 2022 --> Sep 2023 | Trial primary completion date: Sep 2022 --> Sep 2023
almost 2 years ago
Trial completion date • Trial primary completion date
P1, N=37, Active, not recruiting, City of Hope Medical Center | Trial completion date: Dec 2022 --> Dec 2023 | Trial primary completion date: Jun 2022 --> Jun 2023
over 2 years ago
Trial completion date • Trial primary completion date
|
CD19 (CD19 Molecule)
|
CD19 positive
|
cyclophosphamide • etoposide IV • fludarabine IV • Belrapzo (bendamustine RTD) • CD19 CAR T cells
P1, N=71, Active, not recruiting, City of Hope Medical Center | Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2022 --> Sep 2022
P1, N=37, Active, not recruiting, City of Hope Medical Center | N=54 --> 37 | Trial completion date: Dec 2021 --> Dec 2022 | Trial primary completion date: Dec 2021 --> Jun 2022
over 2 years ago
Enrollment change • Trial completion date • Trial primary completion date
|
CD19 (CD19 Molecule)
|
CD19 positive
|
cyclophosphamide • etoposide IV • fludarabine IV • Belrapzo (bendamustine RTD) • CD19 CAR T cells
P1, N=88, Recruiting, City of Hope Medical Center | Trial completion date: Dec 2021 --> Dec 2022 | Trial primary completion date: Dec 2021 --> Jun 2022
over 2 years ago
Trial completion date • Trial primary completion date
P1, N=51, Active, not recruiting, City of Hope Medical Center | Trial completion date: Dec 2021 --> Dec 2022 | Trial primary completion date: Dec 2021 --> Dec 2022
over 2 years ago
Trial completion date • Trial primary completion date
All but 1 patient received a fludarabine/cyclophosphamide (Flu/Cy)-based lymphodepletion regimen prior to receiving CD19CART at 1 of 2 dose levels (DL): DL1=200 million (M) and DL2=600M CAR+ T cells... This clinical study provides evidence for the safety, feasibility and efficacy of Tn/mem-derived CD19CART preceded by Flu/Cy lymphodepletion for the treatment of r/r B-NHL. We plan to pursue this CAR T cell platform in future B-NHL studies, particularly for CNS lymphoma given the encouraging safety and efficacy of CD19CART in the 5 PCNSL patients.
3 years ago
Clinical • P1 data • CAR T-Cell Therapy
|
CD19 (CD19 Molecule)
|
cyclophosphamide • fludarabine IV • CD19 CAR T cells
P2, N=36, Recruiting, City of Hope Medical Center | Trial completion date: Sep 2023 --> Dec 2023 | Trial primary completion date: Sep 2023 --> Dec 2023
over 3 years ago
Clinical • Trial completion date • Trial primary completion date • CAR T-Cell Therapy
P1, N=51, Active, not recruiting, City of Hope Medical Center | Trial completion date: Jun 2021 --> Dec 2021 | Trial primary completion date: Jun 2021 --> Dec 2021
over 3 years ago
Trial completion date • Trial primary completion date
P1, N=88, Recruiting, City of Hope Medical Center | Trial completion date: Sep 2022 --> Dec 2021 | Trial primary completion date: Sep 2022 --> Dec 2021
over 3 years ago
Clinical • Trial completion date • Trial primary completion date • Minimal residual disease